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Introduction
Several studies have shown a high prevalence of rash
induced by nevirapine. The aim of this study was to
identify risk factors associated with the occurrence of
rash during the treatment with nevirapine of HIV-
infected patients.
Materials and methods
A retrospective study was conducted in the infectious
department diseases between January 2007 and October
2013. The study included all HIV-infected patients
receiving HAART regimens that included nevirapine.
The following data were collected: age, sex, CDC classi-
fication of HIV, CD4 and lymphocyte counts, plasma
HIV RNA load, history of drug allergy, concomitant
medication.
Results
During the study period, 268 HIV-infected patients were
treated with HAART regimens including nevirapine.
Nineteen developed cutaneous drug-reactions attributa-
ble to nevirapine (7. 09%). 16 women and 3 men; mean
age: 38 (± 12) years old. The mean initial CD4 was 320
cell/mm3, we observed 17 cases of maculopapular
exanthema and 2 case of DRESS, the hepatic cytolysis
retouved in 5 cases. Female gender (84%), plasma HIV
RNA load > 10 000 copies/ml (100%) constituted risk fac-
tors associated with rash. The niverapine has switched
either Efavirenz or IP; no allergic event was detected
after changing the niverapine.
Conclusion
The number of HIV-infected patients who are newly
exposed to nevirapine is increasing worldwide. To mini-
mize toxicity, clinicians must adhere to dosing guidelines,
avoid prescribing the drug in patients with known
increased risk of toxicity, and promptly recognize toxici-
ties, which are mainly cutaneous and hepatic.
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